Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]
Discontinued
Reference number: GID-TA10413
Following on from information provided to NICE by the company in July 2020 the appraisal of Pembrolizumab in combination for untreated extensive-stage small-cell lung cancer [ID1509] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.